FIG 1.

Serum IgG antibodies to FeLV vaccination phase. All cats were negative for FeLV antibody prior to vaccination on study day 0. Ten of 11 cats in the Nobivac feline 2-FeLV group were positive for FeLV antibody on study days 20 (average S/P ratio, 3.0544 ± 1.007) and 111 (average S/P ratio, 1.002 ± 0.48). The PureVax recombinant FeLV-vaccinated cats and control-group cats remained antibody negative during the vaccination phase of the study. Statistically significant (P = 0.00) differences were seen between the Nobivac feline 2-FeLV group and the Purevax recombinant FeLV group (*) and the control group (**).